Maillard products as biomarkers in cancer

Annals of the New York Academy of Sciences

Volumn 1126, Issue , 2008, Pages 283-287

  Bachmeier, Beatrice E ^a   Nerlich, Andreas G ^b   Rohrbach, Helmut ^b   Schleicher, Erwin D ^c   Friess, Ulrich ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM BOGENHAUSEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Breast cancer; Invasion; Metastasis; N (carboxymethyl)lysine; Oxidative stress

Indexed keywords

6 N CARBOXYMETHYLLYSINE; TUMOR MARKER;

AGED; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CANCER TISSUE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONFERENCE PAPER; CYTOPLASM; FEMALE; GLYCATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALLIARD PRODUCT; METASTASIS; MICROANALYSIS; TUMOR CELL;

EID: 42549090954     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1433.057     Document Type: Conference Paper

References (22)

1. 1 Vlassara, H., R. Bucala & L. Striker. 1994. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for the diabetes and aging. Lab. Invest. 70: 138–151.
2. 2 Schleicher, E.D., E. Wagner & A. Nerlich. 1997. Increased accumulation of the glycoxidation product Nɛ‐(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457–468.
3. 3 Schmidt, A.M., O. Hori & R. Cao, et al. 1996. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 (Suppl 3): S77–80.
4. 4 Liliensiek, B., M.A. Weigand & A. Bierhaus, et al. 2004. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113: 1641–1650.
5. 5 Andrassy, M., J. Igwe & F. Autschbach, et al. 2006. Post‐translationally modified proteins as mediators of sustained intestinal inflammation. Am. J. Pathol. 169: 1223–1237.
6. 6 Tanji, N., G.S. Markowitz, C. Fu, et al. 2000. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am Soc. Nephrol. 11: 1656–1666.
7. 7 Haslbeck, K.M., B. Neundorfer, U. Schlotzer‐Schrehardtt, et al. 2007. Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol. Res. 29: 103–110.
8. 8 Hammes, H.P., H. Hoerauf, A. Alt, et al. 1999. N ɛ (Carboxymethyl)Lysin and the AGE Receptor RAGE colocalize in age‐related macular degeneration. Invest. Ophth. Vis. Sci. 40: 1855–1859.
9. 9 Wendt, T.M., N. Tanji, J. Guo, et al. 2003. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162: 1123–1137.
10. 10 Ledl, F. & E. Schleicher. 1990. New aspects of the maillard reaction in foods and in the human body. Angew. Chem. Int. Ed. Engl. 29: 565–594.
11. 11 Reddys, S., J. Bichler, K.J. Wells‐Knecht, et al. 1995. N ɛ (Carboxymethyl)Lysin is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872–10878.
12. 12 Kislinger, T., C. Fu, B. Huber, et al. 1999. N ɛ (Carboxymethyl)Lysin adducts of proteins are ligands for receptor for advanced gylcation end products that activate cell signalling pathways and modulate gene expression. J. Biol. Chem. 274: 31740–31749.
13. 13 Thorpe, S.R. & J.W. Baynes. 2003. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275–281.
14. 14 Nerlich, A.G., B.E. Bachmeier, E. Schleicher, et al. 2007. Immunomorphological analysis of RAGE receptor expression and NF‐kappaB activation in tissue samples from normal and degenerated intervertebrals discs of various ages. Ann. N. Y. Acad. Sci. 1096: 239–248.
15. 15 Bachmeier, B.E., A.G. Nerlich, et al. 2007. The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell. Physiol. Biochem. 19: 137–152.
16. 16 Bachmeier, B.E. & A.G. Nerlich. 2002. Immunohistochemical pattern of cytokeratins and MMPs in human keratinocyte cell lines of different biological behaviour. Int. J. Oncol. 20: 495–499.
17. 17 Schleicher, E., C. Weigert, H. Rohrbach, et al. 2005. Role of glucoxidation and lipid oxidation in the development of atherosclerosis. Ann. N. Y. Acad. Sci. 1043: 343–354.
18. 18 Minich, T., S. Yokota, R. Dringen, et al. 2003. Cytosolic and mitochondrial isoforms of NADP+dependent isocitrate dehydrogenases are expressed in cultured rat neurons, astrocytes, oligodendrocytes and microglial cells. J. Neurochem. 86: 605–614.
19. 19 Van Heijst, J.W., H.W. Niessen, K. Hoekman, et al. 2005. Advanced glycation end products in human cancer tissue. Ann. N.Y. Acad. Sci. 1043: 725–733.
20. 20 Van Heijst, J.W., H.W. Niessen, R.J. Musters, et al. 2006. Argpyrimidine‐modified heat shock protein 27 in human non‐small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Lett. 241: 309–319.
21. 21 Hsieh, H.L., B.W. Schafer, N. Sasaki, et al. 2003. RAGE is expressed in human tumour tissue. Biochem. Biophys. Res. Com. 307: 375–381.
22. 22 Taguchi, A., D.C. Blood, G. Del Toro, et al. 2000. Blockade of RAGE‐amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354–360.